Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

Abstract

Background: cervical cancer is one of the most common malignancies in women worldwide and its management remains challenging and complex. As Cytochrome4Z1 (CYP4Z1) is overexpressed in many tumours, its expression in cervical cancer is unknown. Therefore, the present study aimed to evaluate CYP4Z1 expression in cervical cancers. Methods: CYP4Z1 expression was immunohistochemically assessed in 100 cases of cervical cancers along with ten normal cervix tissues, and the enzyme’s relationship to several clinicopathological features and survival was explored. Results: CYP4Z1 was strongly expressed in 55% of cervical cancer patients. Normal cervix samples were negative for CYP4Z1 expression. Importantly, this expression was significantly found in patients with the late stage of the disease, lymph node metastasis, and high tumour invasion (p < 0.05). Interestingly, CYP4Z1 expression was significantly correlated with shorter survival times of cervical cancer patients. Univariate analysis showed that CYP4Z1 expression, tumour stage, lymph node metastasis, and tumour invasion were significantly correlated with patient survival (p < 0.05). The multivariate analysis revealed that only CYP4Z1 expression and tumour stage were significantly correlated with patient survival (p < 0.05). Conclusions: CYP4Z1 expression is associated with cervical cancer patients’ survival and may serve as an independent predictor of poor prognosis in cervical cancer patients.

Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients

“…This tendency of CYP4Z1 expression was also observed in lymph node metastasis of breast and cervical cancer patients. 13 , 15 , 16 Our findings are suggestive of the function of CYP4Z1 in colon cancer progression and metastasis.…”

“…CYP4Z1 expression has been reported to be associated with aggressive features in many cancers and is linked with poor survival, particularly in ovarian, prostate, cervical and triple negative breast cancers. 11 , 12 , 15 , 16 In this study, CYP4Z1 expression was associated with low survival rate of colon cancer patients and connoted poor prognosis, which is a novel finding. Moreover, there was a significant association between CYP4Z1 expression and tumour histological grade, the status of lymph node metastasis, and histological stage of colon cancers.…”

“…Several reports demonstrated the expression of CYP4Z1 in a wide variety of primary tumours such as breast, ovary, prostate, bladder and cervix and a lack of expression in normal tissues. 6 , 10–13 , 15 , 16 , 18 , 28 However, there is no information on the presence of CYP4Z1 in metastatic disease. Several studies reported a lack of CYP4Z1 expression in metastatic colon cancers.…”

“… 6 , 7 , 11–15 This overexpression was correlated with an increasing grade of tumour and poor patient outcomes. 11 , 12 , 15 , 16 Moreover, CYP4Z1 was aberrantly expressed at the cell membrane of breast cancer cells and promoted the production of anti-CYP4Z1autoantibodies in the patients’ sera of breast cancer, as opposed to none of the healthy controls. 17 This expression has promoted tumour growth, angiogenesis and the spread of tumour cells.…”

Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study

“…Several metabolic enzymes, particularly members of the cytochrome P450 (CYP) superfamily, are being investigated for their potential role in tumor malignancy [6][7][8]. Of recent interest is a novel member of the CYP1 gene family, CYP1B1, which is an extrahepatic enzyme that is engaged in the metabolism of several endogenous and xenobiotic compounds [9].…”